Novozymes Biopharma and Upperton Limited Granted European Patent for Oncology Technology
News Feb 19, 2009
Novozymes Biopharma and Upperton Limited have announce that the European Patent Office has confirmed the official Decision to Grant a European patent for their targeted drug delivery joint patent application (European patent No 1605979).
The decision, dated 27th October 2008, strengthens the Upperton drug delivery technology portfolio and highlights the growing technology platform that it offers to partner companies. Upperton, along with its collaboration partner Novozymes Biopharma, is now seeking to exploit these technologies with established pharmaceutical companies.
The newly-granted patent describes methods of conjugating antibodies and other targeting agents to protein carriers by means of a heterobifunctional linker. In doing so, it is possible to deliver large quantities of drugs and other agents to selected sites in the body.
The initial focus for the technology will be in oncology. One such application involves using monoclonal antibodies to target recombinant albumin loaded with, for example, a chemotherapeutic agent to cancer cells.
By using the carrier properties of albumin, it is possible to target significant quantities of chemotherapeutic agents or radioactive metal ions to cancer cells, whilst retaining the sensitive binding property of the targeting antibody. The result is a significant increase in the amount of therapeutic agent that can be delivered to its target compared to standard administration methods.
"We are pleased to include this latest patent to our expanding portfolio,'' said Richard Johnson, founding Director of Upperton, "We believe that this patent complements our rP-nano drug delivery platform, an emerging technology based on recombinant protein nanoparticles. The granting of this patent will add significantly to our current achievements with this technology."
Upperton is now in the process of seeking development partners to exploit its drug delivery platform. It is anticipated that the Upperton technology platform will add value across a wide a range of pharmaceutical applications. The current focus is in oncology but other areas that are growing in interest include the delivery of nucleic acids for the rapidly growing siRNA market.
The granting of the new patent underlines the growing relationship that Upperton is creating with its collaborative partner, Novozymes Biopharma.
Dr. Johnson added: "I am extremely pleased to be continuing our collaboration with Novozymes Biopharma. Use of their animal-free, GMP recombinant proteins will be extremely important as we look to commercialize our unique technologies."
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
4000-Year Old DNA Helps Track the Spread of Rice Farming in AsiaNews
Rice farming spread far and wide in ancient Southeast Asia, but how it got there has been a mystery. Now, a study of 4000-year-old DNA—a rare find in this region—suggests it came with farmers migrating from China, where rice farming originated.
Comments | 0 ADD COMMENT
Epigenetics in the nervous system: development and disease
Oct 01 - Oct 03, 2018